This Insight Pharma Report reviews novel technologies designed to enable small and large molecule drugs to efficiently cross the blood-brain barrier. The inability of most drugs to cross the blood-brain barrier is a major bottleneck in the development of central nervous system (CNS) drugs, especially novel drugs aimed at major unmet needs in the CNS area, such as Alzheimer’s disease, Parkinson’s disease, ALS, and stroke.
The report will be of special interest to you if you are involved in the research, development, licensing, or portfolio management of current and potential CNS therapeutics. It will also be of interest to you if you are interested in assessing new opportunities in CNS diseases for your company.
For more information on the report, or to order it, see the CHI Insight Pharma Reports website.
Blood-Brain Barrier: Bridging Options for Drug Discovery and Development
Alan Haberman holds a Ph.D. in biochemistry and molecular biology from Harvard University and has an extensive background in the pharmaceutical and biotechnology industry.
More on the author.
*Report is available for single site, multi-site.